HALF-LIFE FACTOR CONCENTRATES
-
FVIII/IX tenders: how are they done?
Every two or three years, Canadian Blood Services (CBS) and Héma-Québec put out “Requests for Proposals” (RFP) to companies with recombinant factor VIII and IX...
-
CHS 2020 Annual Report
CLICK HERE to access the CHS 2020 Annual Report and the complete Financial Statements.
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the June 2021 review of novel treatments in haemophilia and other bleeding disorders by the European Haemophilia Consortium.
-
Coagulation products | Current and in the pipeline
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates,...
-
CHS replies to Quebec’s INESSS following its shocking report on the funding of Hemlibra
The Institut national d’excellence en santé et en services sociaux (INESSS) released its recommendation on funding Hemlibra (emicizumab) for the treatment of severe hemophilia A...